MaximilianDiehnMD

Thoracic Cancer

Associate Professor, Radiation Oncology, Stanford University Medical Center

Dr. Diehn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
875 Blake Wilbur Dr
Dept of Radiation Oncology Mc5847
Stanford, CA 94305
Phone+1 650-723-6171

Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 2005 - 2009
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2004 - 2005
Stanford University School of MedicineClass of 2004

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

PubMed

59 citations
Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Peiwen Kuo, Scott V. Bratman, David B. Shultz, Rie von Eyben, Cato Chan
Clinical Cancer Research. 2014-11-01
166 citations
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
Christian Rolfo, Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila
Journal of Thoracic Oncology. 2021-10-01
655 citations
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips, William Shi, Matthew P. Deek, Noura Radwan, Su Jin Lim
JAMA Oncology. 2020-05-01

Abstracts/Posters

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA
Maximilian Diehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Methods and Applications of cfDNA Analysis
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Can Cancer Be Found in a Blood Test?February 8th, 2023
Tool Can Reveal Cancer Subtypes by Cell Communities They’re Found InOctober 28th, 2021
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerMarch 30th, 2020
Join now to see all